Integrin Alpha 4 (ITGA4/CD49d) Drug Discovery Landscape & Assay Solutions
- By admin
- 19 Sep 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGA4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGA4/ITGB1 Heterodimer & ITGA4/ITGB7 Heterodimer Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ITGA4 Products |
| Gene Delivery | ITGA4 Lentivirus Premade Particles Full-length ORF for stable cell line construction and cell-based adhesion assays. |
View ITGA4 Products |
| Benchmark Ab | Anti-ITGA4 Recombinant Antibody (Natalizumab Biosimilar) Recombinant positive control for binding and blocking assays. |
View ITGA4 Products |
| Validator | ITGA4 siRNA Set For knockdown verification in target specificity validation. |
View ITGA4 Products |
| Related Target A | ITGB1 (Integrin Beta 1) Pairs with ITGA4 to form VLA-4 (alpha4beta1), key for CNS leukocyte migration. |
View ITGB1 Products |
| Related Target B | ITGB7 (Integrin Beta 7) Pairs with ITGA4 to form LPAM-1 (alpha4beta7), gut-homing cell adhesion receptor. |
View ITGB7 Products |
| Related Target C | MADCAM1 Specific endothelial ligand for alpha4beta7 integrin, critical for IBD therapeutics. |
View MADCAM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent heterodimer stability | HEK293 co-expressed ITGA4/ITGB1 and ITGA4/ITGB7 heterodimers with native folding and glycosylation profiles. |
| Selectivity screening (VLA-4 vs. alpha4beta7) | Both ITGA4/ITGB1 and ITGA4/ITGB7 recombinant proteins and lentivirus-driven cell lines are available for side-by-side profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Natalizumab and Vedolizumab biosimilars) included as positive controls. |
| False Positives | Validated siRNA included for specificity and functional knockdown verification. |
Live ITGA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGA4 therapeutics is intensifying, with major players shifting focus from systemic integrin blockade to organ-selective inhibition. As first-generation therapies like Natalizumab (which targets both alpha4beta1 and alpha4beta7) reach mature clinical use, next-wave R&D is targeting selective gut-homing pathways (alpha4beta7) and oral small-molecule inhibitors to bypass the progressive multifocal leukoencephalopathy (PML) risks associated with systemic immune suppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Biogen, Takeda, Roche | Multiple Sclerosis, Inflammatory Bowel Disease (IBD) | Selectivity Assay (Need high-purity ITGA4/ITGB1 vs ITGA4/ITGB7 heterodimers) |
| Small Molecules | EA Pharma, Morphic Therapeutic | Ulcerative Colitis, Crohn's Disease | Cell-based Adhesion Assay (Need Lentivirus for Stable Cell Line development) |
| Bispecific Antibodies | Academic / Biotech | Refractory Autoimmune, Colorectal Cancer | Target Engagement Validation (Need recombinant MADCAM1 and VCAM1 ligands) |